Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Combined estrogen–androgen formulations
Estradiol cypionate/testosterone cypionate
Другие языки:

    Estradiol cypionate/testosterone cypionate

    Подписчиков: 0, рейтинг: 0
    Not to be confused with Depo-Estradiol, Femandren M, or Folivirin.
    Estradiol cypionate /
    testosterone cypionate
    Estradiol 17 beta-cypionate.svg
    Testosterone cypionate.svg
    Estradiol cypionate (top) and
    testosterone cypionate (bottom)
    Combination of
    Estradiol cypionate Estrogen
    Testosterone cypionate Androgen; Anabolic steroid
    Clinical data
    Trade names Depo-Testadiol, Femovirin, depAndrogyn, others
    Other names EC/TC
    Routes of
    administration    		 Intramuscular injection
    Identifiers
    CAS Number

    Estradiol cypionate/testosterone cypionate (EC/TC), sold under the brand names Depo-Testadiol and Femovirin among others, is an injectable combination medication of estradiol cypionate (EC), an estrogen, and testosterone cypionate (TC), an androgen/anabolic steroid, which is used in menopausal hormone therapy for women. It is specifically indicated for the treatment of moderate-to-severe vasomotor symptoms (i.e., hot flashes), but can also be used for other estrogen indications in women. The medication has also been used to suppress lactation in postpartum women.

    Depo-Testadiol was provided in the form of 10 mL vials containing 2 mg/mL EC and 50 mg/mL TC in an oil solution and was administered by intramuscular injection once every 4 weeks. Conversely, Femovirin was provided in the form of 1 mL ampoules containing 3.5 mg/mL EC (2.4 mg/mL free estradiol) and 90 mg/mL TC (62.9 mg/mL free testosterone) in an oil solution and was administered by intramuscular injection once every 4 to 6 weeks. The elimination half-life of EC in oil by intramuscular injection is approximately 5 days, while the elimination half-life of TC in oil by intramuscular injection is approximately 8 days. EC/TP reportedly has a duration of about 21 days.

    EC/TC likely poses a considerably increased risk of endometrial hyperplasia and cancer in women with intact uteruses (i.e., women who are not hysterectomized) if it is not combined with a progestogen. This is due to the EC component. The concomitant use of a progestogen will abolish such risks. The medication can also cause masculinization, such as acne, deepened voice, hirsutism, and increased sex drive, due to its TC component. Some of these masculinizing symptoms, such as voice deepening, can be irreversible.

    Depo-Testadiol was introduced for medical use in 1954, while Femovirin was introduced for medical use in 1956. An oral tablet product with the same brand name of Femovirin, containing ethinylestradiol and methyltestosterone, was marketed in 1958, and should not be confused with the injectable Femovirin. Depo-Testadiol was discontinued in the United States by 2013. Both Depo-Testadiol and Femovirin have been discontinued in most other countries, but formulations of EC/TC under other brand names continue to be marketed in Taiwan.

    Androgen replacement therapy formulations and dosages used in women
    Route Medication Major brand names Form Dosage
    Oral Testosterone undecanoate Andriol, Jatenzo Capsule 40–80 mg 1x/1–2 days
    Methyltestosterone Metandren, Estratest Tablet 0.5–10 mg/day
    Fluoxymesterone Halotestin Tablet 1–2.5 mg 1x/1–2 days
    Normethandronea Ginecoside Tablet 5 mg/day
    Tibolone Livial Tablet 1.25–2.5 mg/day
    Prasterone (DHEA)b – Tablet 10–100 mg/day
    Sublingual Methyltestosterone Metandren Tablet 0.25 mg/day
    Transdermal Testosterone Intrinsa Patch 150–300 μg/day
    AndroGel Gel, cream 1–10 mg/day
    Vaginal Prasterone (DHEA) Intrarosa Insert 6.5 mg/day
    Injection Testosterone propionatea Testoviron Oil solution 25 mg 1x/1–2 weeks
    Testosterone enanthate Delatestryl, Primodian Depot Oil solution 25–100 mg 1x/4–6 weeks
    Testosterone cypionate Depo-Testosterone, Depo-Testadiol Oil solution 25–100 mg 1x/4–6 weeks
    Testosterone isobutyratea Femandren M, Folivirin Aqueous suspension 25–50 mg 1x/4–6 weeks
    Mixed testosterone esters Climacterona Oil solution 150 mg 1x/4–8 weeks
    Omnadren, Sustanon Oil solution 50–100 mg 1x/4–6 weeks
    Nandrolone decanoate Deca-Durabolin Oil solution 25–50 mg 1x/6–12 weeks
    Prasterone enanthatea Gynodian Depot Oil solution 200 mg 1x/4–6 weeks
    Implant Testosterone Testopel Pellet 50–100 mg 1x/3–6 months
    Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template.

    See also



    Новое сообщение